-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2814 AGILE: Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia and an IDH1 Mutation

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
Monday, December 7, 2020, 7:00 AM-3:30 PM

Pau Montesinos, MD, PhD1,2*, Christian Recher, MD, PhD3,4, Ewa Zarzycka, MD5*, Vadim Doronin, MD, PhD6*, Derek McCulloch, MB, ChB, PhD7*, Susana Vives, MD8*, Rodrigo T. Calado, MD, PhD9, Jun-Ho Jang, MD10*, Yasushi Miyazaki, MD, PhD11, Jianxiang Wang, MD12, Diego A. Gianolio, PhD13*, Scott R. Daigle, MSc13*, Thomas Winkler, MD13*, Vickie Zhang, PhD13* and Peter Paschka, MD14

1Hospital Universitari i Politècnic La Fe, Valencia; CIBERONC, Instituto Carlos III, Madrid, Spain
2Hematology Department, Hospital Universitario La Fe de Valencia,, Valencia, Spain, Spain
3Institut Universitaire du Cancer de Toulouse Oncopole, CHU de Toulouse, Toulouse, France
4Université de Toulouse III, Toulouse, France
5Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
6City Clinical Hospital #40, St. Petersburg, Russian Federation
7Royal Prince Alfred Hospital, Camperdown, Australia
8Hematology Department, ICO - Hospital Germans Trias i Pujol, Badalona, Spain
9University of Sao Paulo, Ribeirão Preto, SP, Brazil
10Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Republic of (South)
11Atomic Bomb Disease Institute, Nagasaki University Hospital, Nagasaki, Japan
12National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
13Agios Pharmaceuticals, Inc., Cambridge, MA
14University Hospital Ulm, Ulm, Germany

Background: Somatic mutations in isocitrate dehydrogenase 1 (IDH1) are reported in 6–10% of patients (pts) with acute myeloid leukemia (AML). Ivosidenib (IVO) is an oral, potent, targeted inhibitor of mutant IDH1 (mIDH1) and is FDA-approved for the treatment of mIDH1 relapsed/refractory AML and for the treatment of mIDH1 newly diagnosed (ND) AML in adults ≥ 75 years (yrs) of age or who have comorbidities precluding the use of intensive chemotherapy (IC). In an ongoing phase 1b study (NCT02677922), 23 ND pts with mIDH1 AML were treated with IVO 500 mg once daily (QD) in combination with subcutaneous azacitidine (AZA) 75 mg/m2 for 7 days (in a 28-day schedule). Pts had a median age of 76 yrs (range 61–88), 12 pts (52%) were ≥ 75 yrs of age, and 12 of 23 were female. Secondary AML was present in 8 (34.8%) pts. As of 19Feb2019, 10 pts (43.5%) remained on study treatment. Pts have been treated for a median of 15 cycles (range 1–30), and the spectrum of adverse events has been consistent with monotherapy experiences with IVO or AZA. Investigators reported 4 cases of IDH differentiation syndrome. Of those, 3 were deemed to be serious adverse events, but all 4 cases resolved. The overall response rate (ORR) was 78.3% (18 of 23 pts), including 60.9% (14 of 23 pts) who achieved a complete remission (CR). Median time to response was 1.8 months (mo) (range 0.7–3.8) and to CR was 3.7 mo (range 0.8–15.7); median response duration has not been reached. Overall survival probability, 12-mo rate, was 82.0%. mIDH1 clearance (< 0.02–0.04%) in bone marrow mononuclear cells was observed in 71% (10 of 14) pts with CR. Here, we report updates to key inclusion criteria and study design of the ongoing AGILE phase 3 study of IVO + AZA in adults with mIDH1 ND AML who are not candidates for intensive treatment.

Methods: AGILE is a global, double-blind, randomized, placebo-controlled, phase 3 study (NCT03173248) that is currently open for enrollment, with participating study centers in North America, South America, Asia, and Europe. Pts are randomized 1:1 to receive either IVO 500 mg QD + AZA 75 mg/m2 subcutaneously or intravenously for 7 days in 28-day cycles, or matched placebo + AZA. Randomization is stratified by region and by de novo vs secondary AML. Key eligibility criteria include pts with previously untreated mIDH1 AML (according to World Health Organization criteria) who are not candidates to receive IC, and who have not received prior treatment with a hypomethylating agent or mIDH1 inhibitor. The recent amendment further specifies criteria for IC-ineligibility as ≥ 75 yrs of age or reduced performance (Eastern Cooperative Oncology Group performance status = 2) or significant organ dysfunction (ie, severe cardiac or pulmonary disorder, impaired renal or liver function). The primary endpoint event-free survival, is defined as the time from randomization until treatment failure, relapse from remission, or death from any cause, whichever occurs first. Treatment failure is defined as failure to achieve CR by Week 24. Key secondary efficacy endpoints have been amended to overall survival, CR rate, CR + CR with partial hematologic recovery rate, and ORR. The favorable safety profile and encouraging clinical activity observed in the phase 1b IVO + AZA combination study for the treatment of IC-ineligible mIDH1 AML warrant a timely and accurate confirmation of the clinical benefit in this difficult to treat population with the phase 3 AGILE study.

Disclosures: Calado: Novartis Brasil S.A.: Speakers Bureau. Miyazaki: NIPPON SHINYAKU CO.,LTD.: Honoraria; Celgene: Honoraria; Astellas Pharma Inc.: Honoraria; Otsuka Pharmaceutical: Honoraria; Chugai Pharmaceutical Co., Ltd.: Honoraria; Kyowa Kirin Co., Ltd.: Honoraria; Novartis Pharma KK: Honoraria; Sumitomo Dainippon Pharma Co., Ltd.: Honoraria. Gianolio: Agios Pharmaceuticals: Current Employment, Current equity holder in private company. Daigle: Agios Pharmaceuticals: Current Employment, Current equity holder in private company. Winkler: Agios Pharmaceuticals: Current Employment, Current equity holder in private company. Zhang: Agios Pharmaceuticals: Current Employment, Current equity holder in private company. Paschka: Pfizer: Consultancy, Speakers Bureau; Sunesis Pharmaceuticals: Consultancy; Amgen: Other; Janssen Oncology: Other; BerGenBio ASA: Research Funding; Otsuka: Consultancy; Celgene: Consultancy, Other: Travel, accommodations or expenses; Novartis: Consultancy, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Speakers Bureau; AbbVie: Other: Travel, accommodation or expenses, Speakers Bureau; Astellas Pharma: Consultancy, Speakers Bureau; Astex Pharmaceuticals: Consultancy; Agios Pharmaceuticals: Consultancy, Speakers Bureau.

*signifies non-member of ASH